查詢結果分析
來源資料
相關文獻
- In-Depth Evaluation of the AJCC 2010 Staging System for Luminal-Like Breast Cancer--An Analysis from a Free-Standing Cancer Hospital
- Late Recurrences in Luminal-like Breast Cancer
- The Effects of Pesticides Chlordane, Dieldrin and Endosulfan on the Growth of Human Breast Cancer Cell Lines MCF-7 and SK-BR-3
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- Cystic Hypersecretory Intraductal Carcinoma of the Breast--Case Report
- Timing of Shoulder Exercise after Modified Radical Mastectomy: A Prospective Study
- 前哨淋巴掃描診斷乳癌早期轉移
- Evaluation of a Simplified Staging System for Prognosis of Hepatocellular Carcinoma
- Measurement of the Quality of Life during Different Clinical Phases of Breast Cancer
- The Prognostic Significance of Pathologic Characteristics of Breast Cancer Patients in Taiwan
頁籤選單縮合
題 名 | In-Depth Evaluation of the AJCC 2010 Staging System for Luminal-Like Breast Cancer--An Analysis from a Free-Standing Cancer Hospital=深入評價2010年AJCC分期系統在管腔樣乳腺癌的應用 |
---|---|
作 者 | 鄭鴻鈞; 余本隆; 洪振芳; 蔡玉真; 陳啟明; 褚乃銘; 曹美華; 劉美瑾; 黃達夫; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 30:1 2014.03[民103.03] |
頁 次 | 頁21-34 |
分類號 | 416.226 |
關鍵詞 | 管腔樣乳癌; 乳癌; 分期系統; 女性荷爾蒙接受器; 第二型人類表皮生長因子接受體; Luminal-like subtype; Breast cancer; Staging system; Estrogen receptor; HER2; |
語 文 | 英文(English) |
中文摘要 | 目的:荷爾蒙受體(HR)陽性的乳癌生物特性不同於人類表皮生長因子受體 2(HER2) 陽性的乳癌。本研究是重新檢視管腔樣(HR 陽性和 HER2 陰性)乳癌 AJCC 分期系統的 適用性。 材料和方法:乳癌病人符合以下標準:1)手術治療為第一種治療,2)在 1990 年和 2008 年間 AJCC2010 病理分期 I-III 的病人,3)HR 陽性,以及 4)HER2 陰性。共計 2051 位 病人包括在本研究裏。我們用 T 分期及 N 分期進行交互檢視,並審視目前 5 年乳癌相關 生存率(BCRS)的相關性。 結果:根據 2010 年 AJCC 分期系統,I 期病人,5 年 BCRS 為 98.9%,IIA 期為 95.8%, IIB 期為 94.0%,IIIA 期為 90.4%,IIIC 期為 75.8%(P <0.001)。重新檢視 T 分期,5 年 BCRS 在 T≦0.5 cm N0 的病人與 T1.1-1.5 cm N0 的病人幾乎一樣(98.4% 比 99.2%); 5 年 BCRS,T1.6-2 cm N1 和 N2 的病人不優於 T>2 cm N1 和 N2 的病人(91.2%與 86.5% 比 94.1%與 88.8%)。依 N 分期,淋巴結陰性到淋巴結侵犯≦5 顆的病人,5 年 BCRS 為 91-98.0%,淋巴結侵犯 6 至 12 顆的病人,5 年 BCRS 為 80%-90%左右,超過 12 顆淋巴 結侵犯的病人,5 年 BCRS 跌破 80%。 結論:2010 年 AJCC 分期系統高估初期管腔樣乳癌相關的死亡風險。原發腫瘤 1.5 cm 是 廣泛淋巴結侵犯和長期存活率的關鍵點。 1-5 顆淋巴結侵犯的病人,5 年 BCRS 率仍然超 過 90%。如果其他醫院的觀察與我們類似,特別是在台灣和亞洲地區,我們可能需要修 改目前的分期系統。 |
英文摘要 | Purpose: Hormonal receptor (HR) positive breast cancer biologically differs from human epidermal growth factor receptor-2 (HER2) positive disease. The purpose of this study was to re-visit the current AJCC staging system in luminal-like (HR positive and HER2 negative) breast cancer. Materials and Methods: A total of 2051 breast cancer patients treated between 1990 and 2008 were included in this study who met the following criteria: 1) surgery as first treatment; 2) pathology stage I-III; 3) HR positive; and 4) HER2 negative. The T- and N-stage were each re-visited to examine their correlation with 5-year breast cancer-related survival (BCRS). Results: According to the AJCC 2010 staging system, the stage I patients showed a 5-year BCRS of 98.9%; stage IIA: 95.8%; stage IIB: 94.0%; stage IIIA: 90.4%, and stage IIIC: 75.8% (p<0.001). Re-visiting the T-classification, the 5-year BCRS in T ≤ 0.5 cm N0 patients was same as that of T 1.1-1.5 cm N0 patients (98.4% versus 99.2%); the 5-year BCRS in T1.6-2 cm N1 and N2 patients were no better than those of T >2 cm N1 and N2 patients (91.2% and 86.5% versus 94.1% and 88.8%). For the nodal stage, the 5-year BCRS were 91-98.0% for node-negative to 5-node positive patients; the 5-year BCRS were around 80-90% for nodal positivity of 6 to 12, and then dropped below 80% for patients with more than 12 involved nodes. Conclusions: The AJCC 2010 staging system overestimated the risk of breast cancer-related death in early stage luminal-like breast cancer in our hospital. Tumor size 1.5 cm is a crucial point to determine extensive nodal involvement and long-term survivals. Patients with 1-5 positive lymph nodes still had a 5-year BCRS rate exceeding 90%. Given our results, a modification for the current staging system is warranted if other hospitals, especially in Taiwan and Asia, have observed similar outcomes. |
本系統中英文摘要資訊取自各篇刊載內容。